GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (NAS:TENX) » Definitions » E10

TENX (Tenax Therapeutics) E10 : $-12,668.50 (As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Tenax Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Tenax Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.190. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-12,668.50 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 47.50% per year. During the past 5 years, the average E10 Growth Rate was 41.40% per year. During the past 10 years, the average E10 Growth Rate was 27.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Tenax Therapeutics was 47.50% per year. The lowest was -20.40% per year. And the median was 6.60% per year.

As of today (2025-01-18), Tenax Therapeutics's current stock price is $6.3696. Tenax Therapeutics's E10 for the quarter that ended in Sep. 2024 was $-12,668.50. Tenax Therapeutics's Shiller PE Ratio of today is .


Tenax Therapeutics E10 Historical Data

The historical data trend for Tenax Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics E10 Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -142,346.00 -107,643.00 -77,193.40 -39,423.30 -15,566.20

Tenax Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19,399.60 -15,566.20 -14,459.50 -12,949.30 -12,668.50

Competitive Comparison of Tenax Therapeutics's E10

For the Biotechnology subindustry, Tenax Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenax Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's Shiller PE Ratio falls into.



Tenax Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tenax Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.19/133.0289*133.0289
=-0.190

Current CPI (Sep. 2024) = 133.0289.

Tenax Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201410 -4,618.410 100.176 -6,133.057
201501 -3,266.910 98.604 -4,407.485
201504 -5,680.060 99.824 -7,569.474
201507 -3,456.150 100.691 -4,566.140
201510 -4,014.090 100.346 -5,321.466
201603 -6,106.680 100.470 -8,085.614
201606 -5,286.110 101.688 -6,915.317
201609 -4,867.490 101.861 -6,356.867
201612 -33,767.000 101.863 -44,098.447
201703 -3,713.820 102.862 -4,802.983
201706 -3,385.680 103.349 -4,357.980
201709 -1,399.310 104.136 -1,787.560
201712 -1,523.510 104.011 -1,948.550
201803 -1,313.840 105.290 -1,659.982
201806 -2,056.790 106.317 -2,573.559
201809 -1,678.670 106.507 -2,096.691
201812 -4,028.500 105.998 -5,055.826
201903 -528.000 107.251 -654.908
201906 -448.000 108.070 -551.469
201909 -528.000 108.329 -648.386
201912 -640.000 108.420 -785.265
202003 -608.000 108.902 -742.704
202006 -368.000 108.767 -450.086
202009 -288.000 109.815 -348.881
202012 -352.000 109.897 -426.092
202103 -2,624.000 111.754 -3,123.527
202106 -160.000 114.631 -185.679
202109 -240.000 115.734 -275.864
202112 -60.800 117.630 -68.760
202203 -172.800 121.301 -189.507
202206 -181.600 125.017 -193.238
202209 -177.600 125.227 -188.666
202212 -69.510 125.222 -73.844
202303 -12.100 127.348 -12.640
202306 -4.000 128.729 -4.134
202309 -6.610 129.860 -6.771
202312 -11.680 129.419 -12.006
202403 -3.120 131.776 -3.150
202406 -1.830 132.554 -1.837
202409 -0.190 133.029 -0.190

Add all the adjusted EPS together and divide 10 will get our e10.


Tenax Therapeutics  (NAS:TENX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Tenax Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenax Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
Executives
Robyn Hunter director 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Chrisopher Thomas Giordano director, officer: CEO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Armistice Capital, Llc director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
June Sherie Almenoff director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Stuart Rich officer: Chief Medical Officer C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Ronald R Blanck director 2001 WALNUT HILL LANE, IRVING TX 75038
Gerald T Proehl director
James P. Mitchum director C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
John P Kelley officer: Chief Executive Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502

Tenax Therapeutics Headlines

From GuruFocus

Tenax Therapeutics Announces Reverse Stock Split

By Stock market mentor Stock market mentor 01-04-2023